Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Bachelot, Thomas, Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Schwartz, Gary N., Pluard, Timothy J., Ricci, Francesco, Gwin, William R., Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Gal-Yam, Einav Nili, Yerushalmi, Rinat, Fasching, Peter A., Kaufman, Peter A., Ashley, Emily J., Perez-Olle, Raul, Hong, Shengyan, Rosales, Minori Koshiji, Gradishar, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
CLINICAL TRIAL UPDATES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839304/
https://www.ncbi.nlm.nih.gov/pubmed/36332179
http://dx.doi.org/10.1200/JCO.21.02937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839304/
https://www.ncbi.nlm.nih.gov/pubmed/36332179
http://dx.doi.org/10.1200/JCO.21.02937

Ejemplares similares